As filed with the Securities and Exchange Commission on June 5, 2015.

 

Registration No. 333-           

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

 

FORM S-8

 

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

 

 

Abbott Laboratories

(Exact name of registrant as specified in its charter)

 

 

ABBOTT LABORATORIES DEFERRED COMPENSATION PLAN

(Full title of the plan)

 

 

Hubert L. Allen

Abbott Laboratories

100 Abbott Park Road

Abbott Park, Illinois 60064-6400

(Name and address of agent for service)

 

Telephone number, including area code, of agent for service:  (224) 667-6100

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

 

 

CALCULATION OF REGISTRATION FEE

 

Title of securities to be registered		Amount to be registered			Proposed maximum offering price per share (a)		Proposed maximum aggregate offering price (a)			Amount of registration fee (a)
Deferred Obligations		$	150,000,000		N/A		$	150,000,000		$	17,430

 

(a)                                 The deferred obligations are unsecured obligations of Abbott Laboratories to pay deferred compensation in the future in accordance with the terms of the Abbott Laboratories Deferred Compensation Plan.

 

 

 

Pursuant to General Instruction E, the contents of Abbott Laboratories Non-Qualified Deferred Compensation Plan Registration Statement on Form S-8 (File no. 333-74220) are incorporated herein by reference.

 

Part II.   Information Required in the Registration Statement

 

Item 8.         Exhibits

 

See Exhibit Index, which is incorporated herein by reference.

 

2

 

SIGNATURES

 

THE REGISTRANT.  Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in unincorporated Lake County, and State of Illinois, on June 5, 2015.

 

	ABBOTT LABORATORIES
	By:	/s/ Miles D. White
		Miles D. White,
		Chairman of the Board and
		Chief Executive Officer

 

3

 

Each person whose signature appears below constitutes and appoints Miles D. White and Hubert L. Allen, and each of them, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this registration statement, and to file the same with all exhibits thereto, and other documents in connection therewith, with the Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

 

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signature		Title		Date
/s/ Miles D. White		Chairman of the Board,		June 5, 2015
Miles D. White		Chief Executive Officer, and
		Director
/s/ Brian B. Yoor		Senior Vice President, Finance and		June 5, 2015
Brian B. Yoor		Chief Financial Officer (Principal
		Financial Officer)
/s/ Robert E. Funck		Vice President, Controller		June 5, 2015
Robert E. Funck		(Principal Accounting Officer)
/s/ Robert J. Alpern, M.D.		Director		June 5, 2015
Robert J. Alpern, M.D.
/s/ Roxanne S. Austin		Director		June 5, 2015
Roxanne S. Austin
/s/ Sally E. Blount, Ph.D.		Director		June 5, 2015
Sally E. Blount, Ph.D.
/s/ W. James Farrell		Director		June 5, 2015
W. James Farrell
/s/ Edward M. Liddy		Director		June 5, 2015
Edward M. Liddy

 

4

 

/s/ Nancy McKinstry		Director		June 5, 2015
Nancy McKinstry
/s/ Phebe N. Novakovic		Director		June 5, 2015
Phebe N. Novakovic
/s/ William A. Osborn		Director		June 5, 2015
William A. Osborn
/s/ Samuel C. Scott III		Director		June 5, 2015
Samuel C. Scott III
/s/ Glenn F. Tilton		Director		June 5, 2015
Glenn F. Tilton

 

5

 

EXHIBIT INDEX

 

Exhibit No.		Description
4		Abbott Laboratories Deferred Compensation Plan, as amended, filed as Exhibit 10.2 to the 2014 Abbott Laboratories Annual Report on Form 10-K.
5		Opinion of Mayer Brown LLP.
23.1		Consent of Mayer Brown LLP is included in the opinion filed as Exhibit 5 hereto.
23.2		Consent of Ernst & Young LLP.
23.3		Consent of Deloitte & Touche LLP.
24		Power of Attorney is included on the signature page.

 

6